Dr. Julie Ottoy
Dr. Julie Ottoy
Postdoctoral researcher, Sunnybrook Research Institute
Verified email at sri.utoronto.ca
Title
Cited by
Cited by
Year
The Cerebrospinal Fluid Aβ 1–42/Aβ 1–40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer’s Disease in a Clinical Setting
E Niemantsverdriet, J Ottoy, C Somers, E De Roeck, H Struyfs, ...
Journal of Alzheimer's Disease 60 (2), 561-576, 2017
412017
Validation of the semiquantitative static SUVR method for 18F-AV45 PET by pharmacokinetic modeling with an arterial input function
J Ottoy, J Verhaeghe, E Niemantsverdriet, L Wyffels, C Somers, ...
Journal of Nuclear Medicine 58 (9), 1483-1489, 2017
202017
18F-PBR111 PET imaging in healthy controls and schizophrenia: test–retest reproducibility and quantification of neuroinflammation
J Ottoy, L De Picker, J Verhaeghe, S Deleye, L Kosten, B Sabbe, ...
Journal of Nuclear Medicine 59 (8), 1267-1274, 2018
192018
Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid-and 18F-FDG-PET imaging
J Ottoy, E Niemantsverdriet, J Verhaeghe, E De Roeck, H Struyfs, ...
NeuroImage: Clinical 22, 101771, 2019
132019
State-associated changes in longitudinal [18F]-PBR111 TSPO PET imaging of psychosis patients: Evidence for the accelerated ageing hypothesis?
L De Picker, J Ottoy, J Verhaeghe, S Deleye, E Fransen, L Kosten, ...
Brain, behavior, and immunity 77, 46-54, 2019
112019
A simulation study on the impact of the blood flow-dependent component in [18F]AV45 SUVR in Alzheimer’s disease
J Ottoy, J Verhaeghe, E Niemantsverdriet, S Engelborghs, S Stroobants, ...
Plos one 12 (12), e0189155, 2017
82017
18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies of cerebral blood flow in Alzheimer's disease: Validation against 15O-H2O PET
J Ottoy, J Verhaeghe, E Niemantsverdriet, E De Roeck, S Ceyssens, ...
Alzheimer's & Dementia 15 (9), 1172-1182, 2019
52019
[P2–363]: EARLY FRAME 18F‐AV45 AND 18F‐FDG‐PET AS PROXIES OF CBF: COMPARISON TO 15O‐H2O PET DATA
J Ottoy, M Miedema, C De Puydt, J Verhaeghe, S Deleye, S Engelborghs, ...
Alzheimer's & Dementia 13 (7S_Part_15), P763-P764, 2017
32017
T7. UPDATED INDIVIDUAL PARTICIPANT DATA META-ANALYSIS CONFIRMS LOWER LEVELS OF THE GLIAL MARKER TSPO IN PSYCHOSIS PATIENTS
P Plavén-Sigray, G Matheson, J Coughlin, S Hafizi, H Laurikainen, J Ottoy, ...
Schizophrenia Bulletin 46 (Supplement_1), S233-S233, 2020
2020
Towards Improved PET Quantification of Amyloid-β Pathology and Cerebral Blood Flow in Alzheimer's Disease: Thesis
J Ottoy
2019
of Neuroinflammation
J Ottoy, LD Picker, J Verhaeghe, S Deleye, L Kosten, B Sabbe, ...
2018
P4‐314: Discordance Between Amyloid‐PET and CSF Amyloid‐β for Diagnosing Alzheimer’S Disease in a Clinical Setting
E Niemantsverdriet, T Van den Bossche, S Van Mossevelde, J Ottoy, ...
Alzheimer's & Dementia 12, P1154-P1154, 2016
2016
P4‐194: Blood Flow–Independent Quantification of [18F]‐AV45 PET Using Model‐Based Kinetics With a Metabolite‐Corrected Arterial Input Function
J Ottoy, J Verhaeghe, E Niemantsverdriet, L Wyffels, C Somers, ...
Alzheimer's & Dementia 12, P1097-P1098, 2016
2016
Test–retest reliability of [18F] PBR111 binding to translocator protein (TSPO) in young healthy control subjects
L De Picker, J Ottoy, S Deleye, J Verhaeghe, S Stroobants, L Wyffels, ...
European Neuropsychopharmacology 2 (26), S214, 2016
2016
THE JOURNAL OF THE ALZHEIMER’S ASSOCIATION
CE Finch, AM Kulminski, M Mandler, E Rockenstein, C Overk, M Mante, ...
The system can't perform the operation now. Try again later.
Articles 1–15